A
Aceragen
Developer of therapeutic treatments intended for rare and ultra-rare diseases
About Aceragen
Aceragen is a biopharmaceutical company that focuses on rare, orphan diseases with no approved treatments. They are dedicated to developing therapies to help patients, and specialize in melioidosis and cystic fibrosis. In addition to their innovative treatments, Aceragen also provides services such as data collection and processing. They are positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023. What sets Aceragen apart from other businesses in the same industry is their commitment to their mission and dedication to helping those in need. They strive to provide the best care and treatments possible, and their services are tailored to meet the needs of their patients.
Source: Dealroom company dataAt a glance
- Founded
- 2021
- Headquarters
- Durham, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
NovaQuest Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aceragen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aceragen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.